(Total Views: 255)
Posted On: 06/01/2017 4:59:47 AM
Post# of 72443
I would keep an eye on their soon to be competitor: ADMP
Their epipen is on track to be approved (June I think) and costs a fraction of Mylans epipen. They had some problems with the FDA: got 2 CRL by the FDA which imo was nothing more than BP pushing back. But they have a good chance of getting approved this time around, especially given the recent climate around Mylan.
Their epipen is on track to be approved (June I think) and costs a fraction of Mylans epipen. They had some problems with the FDA: got 2 CRL by the FDA which imo was nothing more than BP pushing back. But they have a good chance of getting approved this time around, especially given the recent climate around Mylan.
(1)
(0)Scroll down for more posts ▼
